Canada-based healthcare IT firm Myant has acquired mmHg, a physician-led digital health company focused on remote blood pressure monitoring and chronic disease management, for an undisclosed sum.
The acquisition will combine mmHg’s remote monitoring capabilities with Myant’s advanced material and textile computing technology.
It provides continuous, real-time patient data, and enables earlier detection of health risks, along with personalised treatment plans and better management of chronic conditions.
Myant said the acquisition is part of a broader strategy of ‘prevention through precision’ to advance personalised, AI-powered remote healthcare.
It expands the company’s footprint and market reach to the US, where mmHg has a significant existing customer base, including a partnership with A&D Medical.
Also, the acquisition adds new capabilities and aligns with its efforts to leverage AI and advanced materials to improve patient outcomes and extend human life, said Myant.
Myant CEO Tony Chahine said: “Our company is on a mission to make healthy ageing a reality for millions. We want to turn the tide on chronic conditions and redefine what it means to grow older.
“This acquisition enhances our ability to offer comprehensive cardiovascular monitoring and risk management solutions, strengthening our role in transforming digital health and enabling this large ageing demographic to live younger, longer.”
mmHg offers a digital health platform that focuses on delivering care for managing cardiovascular health, particularly in remote settings.
Its advanced software enables healthcare providers to remotely track and analyse blood pressure and several other vital cardiovascular indicators.
mmHg enhances accuracy in decision-making by aligning patient data with clinical best practices, facilitating timely and accurate interventions.
Several top institutions in North America are using the mmHg’s platform to advance patient outcomes and clinical research.
The institutions include Beth Israel Deaconess, Johns Hopkins, Columbia University, NYU, Tulane University, and the University of British Columbia.
mmHg co-founder and chief operating officer Peter Wood said: “The combination of Myant’s cutting-edge textile technology and mmHg’s clinically infused software architecture will no doubt create the next generation of personalised care-delivery.
“Patients will be able to transmit clinical-grade, continuous vitals data feeds to a platform that presents the data in an efficient and clinically relevant manner to care teams.”
